RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerN/A

Registered title, quoted from ClinicalTrials.gov

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Fujian Medical University Union Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06277024, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Locally advanced or metastatic HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histopathology or cytology that cannot be resected;

    Inclusion criterion 2

  3. Has not received radiotherapy, chemotherapy, targeted therapy, or immunotherapy as the primary treatment option for advanced or metastatic diseases in the past; Participants with gastric or gastroesophageal junction adenocarcinoma who have previously received adjuvant or neoadjuvant chemotherapy, radiotherapy, and/or radiochemotherapy are eligible for enrollment as long as the last administration of the previous protocol occurred at least 6 months prior to randomization.

    Inclusion criterion 3

    Suffering from other malignant tumors within the past 5 years, excluding skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ;

    Exclusion criterion 3

  4. ECOG PS: 0-1 points #see Appendix 4#;

    Inclusion criterion 5

  5. WBC ≥ 3 × 109/L

    Inclusion criterion 10

    ANC ≥ 1.5 × 109/L,

    Inclusion criterion 11

    BIL<1.5 times the upper limit of normal value #ULN#,

    Inclusion criterion 14

    ALT and AST<2.5ULN, GPT ≤ 1.5 × ULN;

    Inclusion criterion 15

    Serum Cr ≤ 1ULN, endogenous creatinine clearance rate>60ml/min #Cockcroft Gault formula#

    Inclusion criterion 16

  6. At least one measurable lesion #see Appendix 2#;

    Inclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06277024, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age: 18 years ≤ Age ≤ 75 years;
  • Locally advanced or metastatic HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histopathology or cytology that cannot be resected;
  • Has not received radiotherapy, chemotherapy, targeted therapy, or immunotherapy as the primary treatment option for advanced or metastatic diseases in the past; Participants with gastric or gastroesophageal junction adenocarcinoma who have previously received adjuvant or neoadjuvant chemotherapy, radiotherapy, and/or radiochemotherapy are eligible for enrollment as long as the last administration of the previous protocol occurred at least 6 months prior to randomization.
  • At least one measurable lesion #see Appendix 2#;
  • ECOG PS: 0-1 points #see Appendix 4#;
  • Estimated survival time>3 months;
  • The main organ function is normal and meets the following criteria:
  • Blood routine examination must meet the following criteria#no blood transfusion within 14 days#
  • HB ≥ 100g/L,
  • WBC ≥ 3 × 109/L
  • ANC ≥ 1.5 × 109/L,
  • PLT ≥ 100 × 109/L;
  • Biochemical examination must meet the following standards:
  • BIL<1.5 times the upper limit of normal value #ULN#,
  • ALT and AST<2.5ULN, GPT ≤ 1.5 × ULN;
  • Serum Cr ≤ 1ULN, endogenous creatinine clearance rate>60ml/min #Cockcroft Gault formula#
  • Women of childbearing age must undergo a pregnancy test #serum# within 7 days before enrollment, and the result is negative. They are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug; For males, surgical sterilization or agreement to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug should be considered; 9# Not participating in other clinical studies before and during treatment; 10# The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

  • If a subject meets any of the following conditions, they will not be allowed to enter this study
  • Patients with allergies or suspected allergies to research drugs or similar drugs;
  • Suffering from other malignant tumors within the past 5 years, excluding skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ;
  • Received live vaccine within 4 weeks prior to enrollment or possibly during the study period;
  • Suffering from active autoimmune diseases or having a history of autoimmune diseases within 4 weeks prior to enrollment;
  • Previously received allogeneic bone marrow transplantation or organ transplantation;
  • The patient currently has any disease or condition that affects drug absorption, or the patient is unable to take medication orally;
  • The patient currently has hypertension that cannot be controlled by medication, which is defined as: patients with hypertension who cannot be well controlled with a single antihypertensive drug treatment #systolic blood pressure ≥ 150 mmHg, diastolic blood pressure ≥ 100mmHg#; Or use two or more antihypertensive drugs to control blood pressure in patients;
  • Urinary routine indicates that urine protein is ≥ 2+, and the 24-hour urine protein volume is>1.0g;
  • The patient currently has digestive tract diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectable tumors, or other conditions determined by the researcher that may cause gastrointestinal bleeding or perforation;
  • Patients with significant evidence of bleeding tendency or medical history within the 3 months prior to enrollment #bleeding>30 mL within 3 months, vomiting blood, black stool, and rectal bleeding#, hemoptysis #fresh blood>5 mL within 4 weeks#, or thromboembolic events #including stroke events and/or transient ischemic attacks# within 12 months;
  • Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting surgery within 6 months prior to enrollment; Congestive heart failure is classified by the New York Heart Association #NYHA# as>level 2; Ventricular arrhythmia requiring medication treatment; Electrocardiogram #ECG# shows a QT interval of ≥ 480 milliseconds;
  • Active or uncontrolled severe infection #≥ CTCAE level 2 infection#;
  • Known human immunodeficiency virus #HIV# infection; Known clinically significant history of liver disease, including viral hepatitis [known carriers of hepatitis B virus #HBV# must exclude active HBV infection, i.e. HBV DNA positivity #>1 × 104 copies/mL or>2000 IU/ml#; Known hepatitis C virus infection #HCV# and HCV RNA positivity #>1 × 103 copies/mL, or other types of hepatitis or cirrhosis;
  • According to the judgment of the researchers, patients deemed unsuitable for inclusion in this study.

Quoted from ClinicalTrials.gov, NCT06277024, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06277024, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06277024